Commodore Capital LP 13D and 13G filings for SAB Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-10-03 4:05 pm Purchase | 2025-09-26 | 13G | SAB Biotherapeutics, Inc. SABS | Commodore Capital LP | 4,522,977 9.900% | 2,691,231 (+146.92%) | Filing |
| 2024-02-14 4:05 pm Purchase | 2023-12-31 | 13G | SAB Biotherapeutics, Inc. SABS | Commodore Capital LP | 1,831,746 3.500% | 1,831,746 (New Position) | Filing |